Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition (Q39428029)

11 September 2017

Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition (English)

1 reference

11 September 2017

W Deng

1

1 reference

11 September 2017

Y N Vashisht Gopal

2

1 reference

11 September 2017

A Scott

3

1 reference

11 September 2017

G Chen

4

1 reference

11 September 2017

S E Woodman

5

1 reference

11 September 2017

M A Davies

6

1 reference

11 September 2017

12 January 2012

1 reference

Pigment Cell & Melanoma Research

11 September 2017

1 reference

11 September 2017

25

1 reference

11 September 2017

2

1 reference

11 September 2017

248-258

1 reference

Final version of 2009 AJCC melanoma staging and classification

11 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Phosphorylated 4E-BP1 is associated with poor survival in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2011.00950.X

10.1111/J.1755-148X.2011.00950.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference